Related Experiment Video
Updated: Jun 12, 2026

Identification of Functional Protein Regions Through Chimeric Protein Construction
Published on: January 8, 2019
Identification and characterization of Ch806 mimotopes
Lin Yang1, Hua Jiang, Bizhi Shi
1Shanghai Medical College, Fudan University, No. 130, Dong'an Road, Shanghai, 200032, China.
Abstract:
The chimeric antibody 806 (Ch806) is a promising antitumor agent that recognizes both the epidermal growth factor receptor variant III (EGFRvIII) and the overexpressed epidermal growth factor receptor (EGFR) in cancer tissues but does not recognize the wild type EGFR in normal tissues. However, passive antibody immunization could not produce effective antitumor titers unless the immunization was administered repeatedly over long periods. To overcome this limitation, we generated epitope mimics that bind to Ch806 and tested whether the peptide mimics could induce the production of similar antibodies when actively immunizing mice with the peptides. We used the PH.D-12 phage display peptide library to identify peptides that bind to the monoclonal antibody (mAb) 12H23, which also recognizes similar epitopes of Ch806. Two mimotopes (WHTEILKSYPHE and LPAFFVTNQTQD) were shown to mimic the mAb 12H23 and Ch806 epitope using immunoassays. The mimotopes were conjugated to immunogenic carrier proteins and used to intraperitoneally immunize BALB/c mice. Interestingly, sera from the mice immunized with the isolated mimotopes not only recognize the recombinant or synthetic 806 eptitope, but can also recognize EGFR that is overexpressed in A431 cells and EGFRvIII expressed in Huh7-EGFRvIII cells, whereas sera from mice immunized with the control peptide-KLH (keyhole limpet hemocyanin) and carrier KLH alone failed to show a similar reactivity. Furthermore, in an antibody-dependent cellular cytotoxicity assay (ADCC), the mimotope-induced antibodies specifically lysed human Huh-7-EGFRvIII cells. Our data indicate that the isolated mimotopes reported here may potentially be used as new alternative agents for treating cancer with EGFRvIII expression or EGFR overexpression.
Insights
New peptide mimics can generate antibodies that target cancer-associated epidermal growth factor receptor (EGFR) variants. These mimotopes offer a potential alternative to passive antibody immunization for cancer therapy.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Chimeric antibody 806 (Ch806) targets cancer-specific epidermal growth factor receptor variant III (EGFRvIII) and overexpressed EGFR.
- Passive antibody immunization for Ch806 requires prolonged, repeated administration for effective antitumor titers.
Purpose of the Study:
- To develop novel epitope mimics for Ch806.
- To assess if these peptide mimics can induce similar antibody production through active immunization.
Main Methods:
- Utilized a phage display peptide library to identify mimotopes binding to mAb 12H23, which recognizes similar epitopes to Ch806.
- Conjugated identified mimotopes to carrier proteins (KLH) for immunization of BALB/c mice.
- Evaluated sera reactivity against EGFRvIII and overexpressed EGFR, and performed antibody-dependent cellular cytotoxicity (ADCC) assays.
Main Results:
- Two mimotopes (WHTEILKSYPHE and LPAFFVTNQTQD) successfully mimicked the Ch806 epitope.
- Sera from mimotope-immunized mice recognized recombinant/synthetic Ch806 epitope, overexpressed EGFR (A431 cells), and EGFRvIII (Huh7-EGFRvIII cells).
- Mimotope-induced antibodies demonstrated specific lysis of Huh-7-EGFRvIII cells in ADCC assays.
Conclusions:
- Identified peptide mimotopes can elicit antibodies that recognize cancer-related EGFR targets.
- These mimotopes represent potential alternative therapeutic agents for cancers expressing EGFRvIII or EGFR overexpression.

